Navigation Links
Merrimack Pharmaceuticals To Present Phase I Data On MM-302 And Preclinical Data On Companion Diagnostics Both For The Treatment Of HER2-Positive Breast Cancer
Date:11/27/2012

CAMBRIDGE, Mass., Nov. 27, 2012 /PRNewswire-USNewswire/ -- Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) today announced that Phase I data evaluating the novel agent MM-302 for the treatment of advanced HER2+ breast cancer and preclinical data on potential imaging and biomarker-based diagnostics will be presented  at the 2012 CTRC-AACR San Antonio Breast Cancer Symposium (SABCS), Dec. 4-8, 2012 in San Antonio, Texas.

MM-302 is a nanotherapeutic encapsulation of doxorubicin with anti-HER2 antibody fragments attached to its surface. MM-302 specifically targets cancer cells that overexpress the ErbB2 (HER2) receptor, releasing doxorubicin within the cell and limiting uptake into normal cells. 

"Merrimack believes MM-302 has the potential to achieve better efficacy than current standards of care and lessened risk of cardiac toxicity relative to free doxorubicin," said Ulrik B. Nielsen, Co-Founder and Chief Scientific Officer, Merrimack Pharmaceuticals. "We look forward to presenting both MM-302 Phase I data and preclinical research on its accompanying PET/CT imaging agent, MM-DX-929 at the upcoming Symposium."

Poster Overview:

  • A Phase 1 Study of MM-302, a HER2-targeted Liposomal Doxorubicin, in Patients with Advanced, HER2-positive (HER2+) Breast Cancer (Abstract #: P5-18-09)
    • Poster Session 5: Treatment - HER2-Targeted Therapy
      • Friday, December 7, 2012
      • 5:00 - 7:00 p.m. CT, Exhibit Hall A-B
  • A Novel 64Cu-Liposomal PET Agent (MM-DX-929) Predicts Response to Liposomal Chemotherapeutics in Preclinical Breast Cancer Models (Abstract #: P4-02-05)
    • Poster Session 4: Detection/Diagnosis - Molecular, Functional and Novel Imaging
      • Friday, December 7, 2012
      • 7:00 - 9:00 a.m. CT, Exhibit Hall A-B
  • Quantification of HER2 Expression at the Single Cell Level and HER2 Intratumoral Heterogeneity of Breast Cancer Tissue Samples Using Automated Image Analysis (Abstract #: P1-07-03)
    • Poster Session 1: Prognostic and Predictive Factors – Biomarkers, Methods
      • Wednesday, December 5, 2012
      • 5:00 – 7:00 p.m. CT, Exhibit Hall A-B

About Merrimack Pharmaceuticals, Inc.
Merrimack Pharmaceuticals is a biopharmaceutical company discovering, developing and preparing to commercialize innovative medicines paired with companion diagnostics for the treatment of serious diseases, with an initial focus on cancer. Merrimack applies Network Biology, its proprietary systems biology-based approach to biomedical research, throughout the research and development process. Merrimack currently has five targeted therapeutic oncology candidates in clinical development.

Forward-Looking Statement
Any statements in this press release about future expectations, plans and prospects for Merrimack constitute forward-looking statements within the meaning of The Private Securities Litigation Reform Act of 1995, as amended. Actual results may differ materially from those indicated by such forward-looking statements. Merrimack anticipates that subsequent events and developments will cause its views to change. However, while Merrimack may elect to update these forward-looking statements at some point in the future, Merrimack specifically disclaims any obligation to do so.


'/>"/>
SOURCE Merrimack Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2012 Fourth Quarter Results And Provides Clinical Study Update
2. Unigene and Tarix Pharmaceuticals Enter Definitive Licensing Agreement for "Peptelligence-Engineered" TXA127
3. Actinium Pharmaceuticals Sponsors Webinar on Clinical Use of Alpha Immunotherapy
4. Edison Pharmaceuticals Closes $20M Series F Financing
5. Valeant Pharmaceuticals Announces Publication of Efinaconazole Phase III Results
6. Zacks Sell List Highlights: J.C. Penney, Spirit AeroSystems Holdings, The New York Times and Jazz Pharmaceuticals
7. Cadence Pharmaceuticals CEO Ted Schroeder To Present At The Piper Jaffray 24th Annual Healthcare Conference In New York City On November 28, 2012
8. Avanir Pharmaceuticals To Present At 24th Annual Piper Jaffray Healthcare Conference
9. Arena Pharmaceuticals to Webcast Live Presentation at the Piper Jaffray 24th Annual Healthcare Conference
10. AcelRx Pharmaceuticals to Present at the Piper Jaffray 24th Annual Healthcare Conference
11. Anthera Pharmaceuticals to Present at the Piper Jaffray Health Care Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/21/2017)... 2017 Micro Guide Catheters Market: Overview ... Micro Guide Catheters are used ... clinics and ambulatory surgery centers etc. Micro guide ... selection of micro guide catheter depends on the ... body. Micro guide catheters are available in different ...
(Date:2/21/2017)... , Feb. 21, 2017  Luminex Corporation (NASDAQ: ... of directors has authorized the initiation of a quarterly cash ... This initial cash dividend will be payable on April 14, ... business on March 24, 2017. The board ... quarterly cash dividend of $0.06 to holders of its common ...
(Date:2/21/2017)...  /PR Newswire/ -- UBM Medica,s Eye Care Group ... of Modern Retina ( www.modernretina.com ), a ... Built upon the success of Ophthalmology Times ... innovations in the areas of retinal surgery, clinical information, ... current informational needs and filling existing educational gaps, ...
Breaking Medicine Technology:
(Date:2/22/2017)... ... 2017 , ... FPS is a nonprofit mental health agency ... 1977, our organization was at the forefront in working with veterans with PTSD-related ... evident and served as the catalyst for the establishing the agency. , Run ...
(Date:2/22/2017)... ... February 22, 2017 , ... ... so many different solutions on the market, it is easy to start feeling ... Premier Locksmith offers a complimentary security consultation. , Home Security Hardware Choices, ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... by itself - the Vectorâ„¢ Series Multi-Cook Oven offers up to four ovens ... featuring exclusive Structured Air Technologyâ„¢ for unmatched evenness in cooking. Alto-Shaam has partnered ...
(Date:2/22/2017)... , ... February 22, 2017 , ... ... and the number of African American/Black students who want to become physicians. PMF ... pursue their careers as physicians in the Oakland/San Francisco Northern California, Bay Area. ...
(Date:2/21/2017)... ... 21, 2017 , ... Robins & Morton celebrated the grand ... Feb. 21. , The celebration began with a ribbon cutting event at 10:30 ... team and tribal leadership. , Choctaw Nation Durant Regional Medical Clinic is ...
Breaking Medicine News(10 mins):